Postepy Dermatologii I Alergologii最新文献

{"title":"Association between single nucleotide polymorphisms of interleukin-35 genes and atopic dermatitis.","authors":"Weronika Zysk, Jolanta Gleń, Monika Zabłotna, Roman J Nowicki, Magdalena Trzeciak","doi":"10.5114/ada.2024.141783","DOIUrl":"https://doi.org/10.5114/ada.2024.141783","url":null,"abstract":"<p><strong>Introduction: </strong>The pathogenesis of atopic dermatitis (AD) involves complex interactions between environmental factors, the skin microbiome, epidermal barrier defects, and altered immune responses that develop on a not fully understood specific genetic background.</p><p><strong>Aim: </strong>We aimed to evaluate the contribution of single nucleotide polymorphisms (SNPs) in the IL-35 genes (<i>IL-12A</i> and <i>EBI3</i>) towards AD susceptibility and clinical characteristics of AD in the Polish population. Two SNPs (rs568408, rs582054) in <i>IL-12A</i> and one SNP (rs428253) in <i>EBI3</i> were selected.</p><p><strong>Material and methods: </strong>Blood samples were collected from 202 AD patients and 178 healthy individuals. SNPs in IL-35 genes were analysed by the polymerase chain reaction with sequence-specific primers (SSP-PCR) method.</p><p><strong>Results: </strong>For <i>IL-12A</i> rs568408, the AA genotype was significantly linked to increased odds of AD (OR = 34.61; 95% CI: 2.06-579.97, <i>p</i> = 0.0137) and marginally associated with normal total serum IgE levels (OR = 2.82; 95% CI: 0.97-8.16; <i>p</i> = 0.05), while the GA genotype showed significantly reduced odds of AD (OR = 0.53; 95% CI: 0.34-0.81; <i>p</i> = 0.0035). In the context of <i>IL-12A</i> rs582054, TT genotype carriers had increased odds of AD (OR = 2.05; 95% CI: 1.08-3.85; <i>p</i> = 0.03). Patients with the GG genotype of <i>EBI3</i> rs428253 had decreased odds of high total serum IgE levels (OR = 0.42; 95% CI: 0.20-0.86; <i>p</i> = 0.02) and milder pruritus severity compared to CC genotype carriers (4.12 vs. 7.50; <i>p</i> = 0.02).</p><p><strong>Conclusions: </strong>IL-35 genetic variations appear to play a role in AD pathogenesis.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 4","pages":"415-422"},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabidiol modulation of immune cell function: <i>in vitro</i> insights and therapeutic implications for atopic dermatitis.","authors":"Nada Chaoul, Stefano Palazzo, Alessandro Cinquantasei, Vincenzo Aresta, Concetta De Chirico, Marcello Albanesi","doi":"10.5114/ada.2024.142182","DOIUrl":"https://doi.org/10.5114/ada.2024.142182","url":null,"abstract":"<p><strong>Introduction: </strong>Cannabidiol (CBD) exhibits neuroprotective, anti-inflammatory, and immunomodulatory properties, making it a promising candidate for addressing inflammatory skin disorders like atopic dermatitis.</p><p><strong>Aim: </strong>This study aimed to (i) investigate CBD's impact on lymphocyte proliferation and lymphocyte viability; (ii) assess <i>in vitro</i> cytotoxicity U937 cells (a human promonocytic cell line) of CBD/cytotoxicity of CBD on U937 cells; (iii) provide insights into CBD immunomodulatory potential, and (iv) evaluate suitability of CBD for treating inflammatory skin conditions.</p><p><strong>Material and methods: </strong>To this aim PBMCs from healthy donors were cultured with mitogen and two different CBD doses (0.1 and 1 mg/ml), assessing B and T cell proliferation through flow cytometry. CBD inhibited mitogen-induced lymphocyte proliferation, reducing the percentage of proliferating T and B cells. Notably, both CBD doses did not exhibit cytotoxicity on lymphocytes as revealed by viability assessment. We also analysed the effect of CBD on U937 cells using an optical microscopy approach. Interestingly, the higher dose of CBD exerted a cytotoxic effect on U937 cells, while the lower dose was well tolerated.</p><p><strong>Results: </strong>We analysed the effect of an adjuvant treatment for atopic dermatitis with a CBD-containing cleansing cream in reducing itch. Notably, the treatment with the CBD-containing cleansing cream significantly reduced itch in patients suffering from atopic dermatitis.</p><p><strong>Conclusions: </strong>These findings affirm CBD's immunomodulatory characteristics, emphasizing its potential therapeutic application in inflammatory skin disorders.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 4","pages":"408-414"},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed drug hypersensitivity to anti-tuberculosis drug: a new desensitization scheme.","authors":"İsmet Bulut, Zeynep Yegin Katran, Aylin Babalık, Metin Keren, Fatma Merve Tepetam","doi":"10.5114/ada.2024.142187","DOIUrl":"https://doi.org/10.5114/ada.2024.142187","url":null,"abstract":"<p><strong>Introduction: </strong>Tuberculosis is a communicable illness and one of the leading causes of death, especially in developing countries like Turkey. One of the problems that must be managed well in the treatment of tuberculosis is drug hypersensitivity. The first-line agents are very important for the success of treatment. Alternative drugs are more toxic and less successful in treatment. Therefore, it is very important to be able to include first-line drugs in the post-hypersensitivity regimen. At this point, the success of desensitization comes to the fore. There are fewer studies on rapid drug desensitization in delayed-type drug hypersensitivity to anti-tuberculosis drugs.</p><p><strong>Aim: </strong>The primary aim of the study was to determine the prevalence of delayed-type hypersensitivity reactions in drug-sensitive cases; the secondary aim was to determine the appropriate treatment management.</p><p><strong>Material and methods: </strong>This was a retrospective study. Demographic features, tuberculosis diagnostic indicator, clinical signs of developing a hypersensitivity reaction, reaction time, desensitization scheme and treatment were evaluated.</p><p><strong>Results: </strong>A total of 41 tuberculosis cases were included in the study. Twenty-six of the cases were male; mean age (mean ± SD) 55.44 ±16.93 years; 70.7% of them were diagnosed bacteriologically; 70.7% of them were diagnosed with pulmonary tuberculosis. The most common skin finding was maculopapular drug eruption. The development time (mean ± SD) of the reaction in patients who developed a reaction was 34.93 ±39.62 days. The responsible agent could be identified in 15 reactions. The most common drug responsible for the reaction was rifampicin. Successful desensitization was achieved in 19 (46.3%) cases with the sensitive regimen. The duration of treatment was 8.97 ±3.44 months. When evaluated in terms of treatment results, cure and treatment completion were accepted as treatment success. In this case, 30 (73.2%) patients successfully completed the treatment.</p><p><strong>Conclusions: </strong>Our study is one of the largest series in which delayed-type hypersensitivity develops under tuberculosis treatment and the desensitization scheme is recommended. A practical, easy desensitization scheme had been shared in this paper.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 4","pages":"400-407"},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale for the topical use of a combination of diphenhydramine hydrochloride and lidocaine hydrochloride in the symptomatic treatment of histamine-dependent allergic and inflammatory skin reactions, accompanied by pruritus.","authors":"Zbigniew Doniec, Małgorzata Sielska, Tomasz Wróbel, Roman J Nowicki","doi":"10.5114/ada.2024.141098","DOIUrl":"https://doi.org/10.5114/ada.2024.141098","url":null,"abstract":"<p><strong>Introduction: </strong>Allergic reactions caused by external factors are treated with medicinal products containing antihistamines, therefore their action is delayed in time. Combination of antihistamines and fast-acting analgesics may help to reduce discomfort associated with cutaneous reactions.</p><p><strong>Aim: </strong>To evaluate efficacy and safety of the combination topical gel containing diphenhydramine hydrochloride 20 mg/g and lidocaine hydrochloride 10 mg/g over placebo in the treatment of local skin inflammatory and allergic reactions.</p><p><strong>Material and methods: </strong>A study was a single-centre, single-dose, randomized, double-blind, two-treatment, two-period, two-sequence cross-over clinical trial (<i>n</i> = 44) in healthy subjects. Local skin inflammatory and allergic lesions were induced by the provocative test with histamine in healthy subjects. For all parameters recorded with the Visual Analogue Scale (VAS), the area under the curve (AUC) was calculated and the peak itch intensity was noted for every subject in response to the skin prick test. The primary endpoint of the study was the difference in AUC calculated from the intensity of itch for test product A (diphenhydramine hydrochloride 20 mg/g and lidocaine hydrochloride 10 mg/g, gel) and placebo product B.</p><p><strong>Results: </strong>The results revealed that itching intensity AUC was significantly greater for product B than for product A, on average by 2.05 points. A decrease in itching intensity was observed from the second minute after application of the test product.</p><p><strong>Conclusions: </strong>The study provided evidence for differences in efficacy between the product tested and placebo.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 4","pages":"388-394"},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Premature chondrodermatitis nodularis (adults < 61 years) and infection with human immunodeficiency virus: a matched multi-centre case-control study in North Spain.","authors":"Jimena Carrero Martín, Francisco Vazquez López, Cristina Galache Osuna, Celia Gómez de Castro, Carla Díaz Louzao, Marcos González López","doi":"10.5114/ada.2024.142256","DOIUrl":"https://doi.org/10.5114/ada.2024.142256","url":null,"abstract":"","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 4","pages":"426-428"},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mycobacterium marinum infection on the thigh and hip masquerading as tinea cruris.","authors":"Zhimin Hao, Hao Song, Pangen Cui, Zhi Xiang","doi":"10.5114/ada.2024.141116","DOIUrl":"https://doi.org/10.5114/ada.2024.141116","url":null,"abstract":"","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 4","pages":"423-425"},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of refractory heat urticaria with omalizumab.","authors":"Attilio Di Girolamo, Andrea Miniello, Rossella Casella, Marcello Albanesi, Eustachio Nettis","doi":"10.5114/ada.2024.142183","DOIUrl":"https://doi.org/10.5114/ada.2024.142183","url":null,"abstract":"","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 4","pages":"429-431"},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review.","authors":"Hio Fong Leong, Wen-Hui Wang, Fen Peng","doi":"10.5114/ada.2024.141128","DOIUrl":"10.5114/ada.2024.141128","url":null,"abstract":"<p><strong>Introduction: </strong>Palmoplantar pustulosis (PPP) is a complex inflammatory skin disease. Currently, no standardized treatments exist, and traditional systemic therapies often display limited effectiveness and substantial adverse effects. Biologics, however, have shown potential for enhanced clinical outcomes in psoriasis patients, thereby prompting this investigation into their applicability in PPP treatment.</p><p><strong>Aim: </strong>This study constitutes the first comprehensive review to assess the effectiveness and underlying mechanisms of biologics for PPP.</p><p><strong>Material and methods: </strong>We conducted a PubMed search to identify studies on biologics for PPP from 1992 onward. The review focused on assessing the efficacy of biologics targeting cytokines like IL-1, IL-8, IL-17, IL-12/23, IL-36, and TNF-α.</p><p><strong>Results: </strong>Biologics for PPP are generally less effective than for psoriasis. Secukinumab and guselkumab, IL-17 and IL-23 inhibitors respectively, have shown better results compared to other biologics in trials. However, the effectiveness of other biologics remains uncertain due to limited data.</p><p><strong>Conclusions: </strong>More research is needed to find effective treatments for PPP, and selecting the right biologic for each patient is challenging.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 3","pages":"262-269"},"PeriodicalIF":1.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11253319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141725095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"miR-22 negatively regulating NOD-like receptor protein 3 gene in the proliferation, invasion, and migration of malignant melanoma cells.","authors":"Hongyan Liu, Wenlian Huang, Xiaoshu Pu, Yi Chen, Yinbin Zheng, Ying Lei, Ting Jiang","doi":"10.5114/ada.2024.140521","DOIUrl":"10.5114/ada.2024.140521","url":null,"abstract":"<p><strong>Introduction: </strong>Malignant melanoma (MM) is a highly aggressive skin tumour.</p><p><strong>Aim: </strong>To investigate whether miR-22 is involved in the proliferation, invasion, and migration of melanoma cells (MCs) by negatively regulating NOD-like receptor protein 3 (NLRP3) gene.</p><p><strong>Material and methods: </strong>Human MCs (WM239a) and human epidermal melanocytes (HEM) were used as study material. The expression levels of miR-22 and NLRP3 were detected by qRT-PCR. The expression of NLRP3 protein was determined by Western blot (WB) analysis. The effects of miR-22 and NLRP3 on the proliferation, invasion, and migration of MCs were evaluated by cell counting kit-8 (CCK-8), Transwell cell invasion assay, and scratch assay.</p><p><strong>Results: </strong>The expression of miR-22 was clearly lower in WM239a than in HEM. Up-regulation of miR-22 expression in WM239a clearly raised the expression of miR-22, Caspase-1, and E-cadherin and the apoptotic rate of WM239a; however, the levels of interleukin-1β (IL-1β) and NLRP3, cell proliferation activity, invasion and migration ability were clearly decreased. The negative regulation of NLRP3 by miR-22 may play a major role in activities of MM.</p><p><strong>Conclusions: </strong>Further studies will help to reveal the molecular details of this regulatory mechanism and provide new therapeutic strategies.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 3","pages":"284-291"},"PeriodicalIF":1.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11253316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141725060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy of ultrasound-guided chondroitin polysulfate from bovine trachea combined with fractional CO₂ laser in the treatment of scar after burn repair.","authors":"Jianjun Zhou, Xiaojun Huang, Meijie Chen, Xiaofang Chen, Jiong Chen","doi":"10.5114/ada.2024.141110","DOIUrl":"10.5114/ada.2024.141110","url":null,"abstract":"<p><strong>Introduction: </strong>One common and very upsetting side effect of burn injuries is scarring, which presents serious difficulties for patients and medical professionals alike.</p><p><strong>Aim: </strong>To assess a new therapeutic approach for treating scars following burn repair procedures in terms of its clinical efficacy.</p><p><strong>Material and methods: </strong>This method administers Hirudoid under ultrasound guidance in addition to fractional CO₂ laser treatment. An extensive analysis of the effects of this combination treatment on functional results, patient satisfaction, and scar appearance is being conducted as part of this research. Fractional CO₂ laser treatment is utilized for its capacity to stimulate collagen remodelling and decrease scar hypertrophy, while Hirudoid, a topical medicine containing heparinoid, is used to minimize inflammation and enhance tissue healing. Enrolling patients who have had burn repair surgery is the goal of a quasi-experimental study. Conventional scar care methods are performed on the control group, whereas the experimental group is treated with fractional CO₂ laser therapy after applying Hirudoid under ultrasound guidance. Throughout the research period, clinical evaluations are carried out on a regular basis. These evaluations cover scar features, pain thresholds, and patient-reported results.</p><p><strong>Results: </strong>The first findings show that the experimental group significantly outperformed the control group in terms of overall look, pigmentation, and scar texture. Functional examinations point to possible improvements in terms of scar flexibility and the range of motion, while patient-reported outcomes show improved satisfaction with the combination therapy. In order to guarantee the combination therapy's viability and tolerance in a clinical context, its side effects and safety profiles are also extensively assessed. In order to improve scar management following burn healing, the study intends to provide important insights into the creation of more patient-friendly and successful therapies.</p><p><strong>Conclusions: </strong>A potential approach to enhancing the clinical results of burn scar treatment is the study of fractional CO₂ laser therapy in conjunction with ultrasound-guided Hirudoid. Enhancing scar management tactics via the combination of sophisticated technology and therapy modalities may eventually improve the quality of life for burn injury victims.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 3","pages":"314-327"},"PeriodicalIF":1.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11253313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141725097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}